Standard BioTools Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Standard BioTools Inc. (LAB) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $274.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2025-03-11
- 2024-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $274.00K.
- 2024-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $432.00.
- 2024-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $453.00.
- 2024-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.76K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2024-12-31 | $274.00K 10-K · filed 2025-03-11 | |
| 2024-09-30 | $432.00 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $453.00 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $1.76K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $0.00 10-K · filed 2025-03-11 | $906.00 10-Q · filed 2024-05-09 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-11 | |
| 2011-12-31 | $0.00 10-K · filed 2013-03-12 | |
| 2011-09-30 | $0.00 10-Q · filed 2012-11-09 | |
| 2011-06-30 | $0.00 10-Q · filed 2012-08-14 | |
| 2010-12-31 | $1.05M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |